OBJECTIVE: To report that antibodies to synaptic proteins may occur in association with slow, progressive cognitive decline. METHODS: A total of 24 patients with progressive cognitive dysfunction of unclear etiology were examined for onconeuronal and synaptic receptor antibodies. The effect of serum was examined in cultures of dissociated mouse hippocampal neurons. RESULTS: Seven patients had immunoglobulin A (IgA), but no immunoglobulin G (IgG), antibodies against NMDA receptor (NMDAR). Anti-NMDAR IgA positive patients' serum, but not serum from control individuals, caused dramatic decrease of the levels of NMDAR and other synaptic proteins in neurons, along with prominent changes in NMDAR-mediated currents. These effects correlated with the titer of IgA NMDAR antibodies and were reversed after removing patients' serum from the culture media. When available, comprehensive clinical assessment and brain metabolic imaging showed neurologic improvement after immunotherapy. CONCLUSIONS: A subset of patients with slowly progressive cognitive impairment has an underlying synaptic autoimmunity that decreases the density of NMDAR and other synaptic proteins, and alters synaptic currents. This autoimmunity can be demonstrated examining patients' serum and CSF for NMDAR IgA antibodies, identifying possible candidates for immunotherapy.
OBJECTIVE: To report that antibodies to synaptic proteins may occur in association with slow, progressive cognitive decline. METHODS: A total of 24 patients with progressive cognitive dysfunction of unclear etiology were examined for onconeuronal and synaptic receptor antibodies. The effect of serum was examined in cultures of dissociated mouse hippocampal neurons. RESULTS: Seven patients had immunoglobulin A (IgA), but no immunoglobulin G (IgG), antibodies against NMDA receptor (NMDAR). Anti-NMDAR IgA positive patients' serum, but not serum from control individuals, caused dramatic decrease of the levels of NMDAR and other synaptic proteins in neurons, along with prominent changes in NMDAR-mediated currents. These effects correlated with the titer of IgA NMDAR antibodies and were reversed after removing patients' serum from the culture media. When available, comprehensive clinical assessment and brain metabolic imaging showed neurologic improvement after immunotherapy. CONCLUSIONS: A subset of patients with slowly progressive cognitive impairment has an underlying synaptic autoimmunity that decreases the density of NMDAR and other synaptic proteins, and alters synaptic currents. This autoimmunity can be demonstrated examining patients' serum and CSF for NMDAR IgA antibodies, identifying possible candidates for immunotherapy.
Authors: Simon B Eickhoff; Klaas E Stephan; Hartmut Mohlberg; Christian Grefkes; Gereon R Fink; Katrin Amunts; Karl Zilles Journal: Neuroimage Date: 2005-05-01 Impact factor: 6.556
Authors: I Apostolova; M Lindenau; J Fiehler; O Heese; F Wilke; M Clausen; S Stodieck; R Buchert Journal: Nuklearmedizin Date: 2008 Impact factor: 1.379
Authors: Josep Dalmau; Erdem Tüzün; Hai-yan Wu; Jaime Masjuan; Jeffrey E Rossi; Alfredo Voloschin; Joachim M Baehring; Haruo Shimazaki; Reiji Koide; Dale King; Warren Mason; Lauren H Sansing; Marc A Dichter; Myrna R Rosenfeld; David R Lynch Journal: Ann Neurol Date: 2007-01 Impact factor: 10.422
Authors: Michael D Geschwind; K Meng Tan; Vanda A Lennon; Ramon F Barajas; Aissa Haman; Christopher J Klein; S Andrew Josephson; Sean J Pittock Journal: Arch Neurol Date: 2008-10
Authors: Josep Dalmau; Amy J Gleichman; Ethan G Hughes; Jeffrey E Rossi; Xiaoyu Peng; Meizan Lai; Scott K Dessain; Myrna R Rosenfeld; Rita Balice-Gordon; David R Lynch Journal: Lancet Neurol Date: 2008-10-11 Impact factor: 44.182
Authors: C Hammer; B Stepniak; A Schneider; S Papiol; M Tantra; M Begemann; A-L Sirén; L A Pardo; S Sperling; S Mohd Jofrry; A Gurvich; N Jensen; K Ostmeier; F Lühder; C Probst; H Martens; M Gillis; G Saher; F Assogna; G Spalletta; W Stöcker; T F Schulz; K-A Nave; H Ehrenreich Journal: Mol Psychiatry Date: 2013-09-03 Impact factor: 15.992
Authors: Ludger Tebartz van Elst; Karl Bechter; Harald Prüss; Alkomiet Hasan; Jo Hann Steiner; Frank Leypoldt; Dominique Endres Journal: Nervenarzt Date: 2019-07 Impact factor: 1.214